Search This Blog

Thursday, December 5, 2019

Epizyme +2.6% as Morgan Stanley joins other bulls

Epizyme (NASDAQ:EPZM) is up 2.6% postmarket after its last cautious analyst holdout joined others in the bull column.
Morgan Stanley raised its recommendation to Overweight from Equal Weight, where it was a lone holdout.
The firm set its price target to $22, implying 44% upside.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)